IFNG and neoplasm: Interestingly, the frequency of classical CD14+ HLA-DR+ monocytes prior to therapy was found to be a strong predictor of response, thought to reflect myeloid expansion triggered by IFNγ produced by activated tumor-specific and infiltrated T cells in patients who are more likely to become responders.